Treatment of Borrmann Type IV Gastric Cancer with a Neoadjuvant Chemotherapy Combination of Docetaxel, Cisplatin and 5-Fluorouracil/Leucovorin

被引:20
|
作者
Sun, X-C [2 ]
Lin, J. [2 ]
Ju, A-H [1 ]
机构
[1] Yantai Yuhuangding Hosp, Dept Gastroenterol, Yantai 264000, Peoples R China
[2] Yantai Yuhuangding Hosp, Dept Surg Oncol, Yantai 264000, Peoples R China
关键词
CISPLATIN; DOCETAXEL; 5-FLUOROUGACIL; ANTICANCER AGENTS; NEOADJUVANT CHEMOTHERAPHY; BORRMANN TYPE IV GASTRIC CARCINOMA; EFFICACY; CONTINUOUS-INFUSION; 5-FLUOROURACIL; PHASE-II; CLINICOPATHOLOGICAL FEATURES; FOLINIC ACID; PACLITAXEL; CARCINOMA;
D O I
10.1177/147323001103900605
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
This study evaluated the efficacy and safety of docetaxel, cisplatin and 5-fluorouracil/leucovorin as neoadjuvant chemotherapy before surgery (NCT group; n = 29) compared with postoperative chemotherapy alone (non-NCT group; n =26) in the treatment of Borrmann type IV gastric carcinoma. Primary tumour response rate, surgical parameters, incised-edge residue rate, lymphatic metastasis status and side-effects were evaluated. The overall response rate was 58.6% in the NCT group, which included three (10.3%) patients in complete remission and 14 (48.3%) patients in partial remission. The postoperative pathological complete response rate was 6.9% (two patients) in the NCT group. NCT was associated with a significant increase in the radical resection rate and a significant decrease in the rate of incised-edge residues, compared with postoperative chemotherapy alone. Side-effects due to NCT were minimal and resolved with appropriate treatment. There were no chemotherapy-related deaths in either group. In conclusion, docetaxel, cisplatin and 5-fluorouracil/leucovorin was an effective and well-tolerated NCT regimen for Borrmann type IV gastric cancer.
引用
收藏
页码:2096 / 2102
页数:7
相关论文
共 50 条
  • [21] Docetaxel (Taxotere), cisplatin, UFT, and leucovorin combination chemotherapy in advanced gastric cancer
    Oh, SC
    Park, KH
    Choi, IK
    Yoon, SY
    Kim, SJ
    Seo, JH
    Choi, CW
    Kim, BS
    Shin, SW
    Kim, JS
    Kim, YH
    BRITISH JOURNAL OF CANCER, 2005, 92 (05) : 827 - 831
  • [22] Paclitaxel, 5-fluorouracil, and leucovorin combination chemotherapy as first-line treatment in patients with advanced gastric cancer
    Que, Wan-Cai
    Huang, Yan-Fang
    Lin, Xiao-Yan
    Lan, Yan-Qin
    Gao, Xin-Yan
    Wang, Xin-Li
    Wu, Ri-Ping
    Du, Bin
    Huang, Xiao-Bin
    Qiu, Hong-qiang
    Zhong, Dong-Ta
    ANTI-CANCER DRUGS, 2019, 30 (03) : 302 - 307
  • [23] Combination chemotherapy comprising 5-fluorouracil, leucovorin, etoposide, and cis-diamminedichloroplatinum for the treatment of advanced gastric cancer
    Fumiro Mochizuki
    Masashi Fujii
    Yuichi Kasakura
    Motoo Yamagata
    Mitsugu Kochi
    Kazuhiko Wakabayashi
    Noriaki Kanamori
    Tadatoshi Takayama
    Journal of Cancer Research and Clinical Oncology, 2002, 128 : 493 - 496
  • [24] Sequential chemotherapy with cisplatin, leucovorin, and 5-fluorouracil followed by docetaxel in previously untreated patients with metastatic gastric cancer: a phase II study
    Vincenzo Catalano
    Bruno Vincenzi
    Paolo Giordani
    Francesco Graziano
    Daniele Santini
    Anna Maria Baldelli
    Paolo Alessandroni
    Gaia Schiavon
    David Rossi
    Virginia Casadei
    Silvia D’Emidio
    Stefano Luzi Fedeli
    Giuseppe Tonini
    Giammaria Fiorentini
    Gastric Cancer, 2012, 15 : 419 - 426
  • [25] Combination chemotherapy comprising 5-fluorouracil, leucovorin, etoposide, and cis-diamminedichloroplatinum for the treatment of advanced gastric cancer
    Mochizuki, F
    Fujii, M
    Kasakura, Y
    Yamagata, M
    Kochi, M
    Wakabayashi, K
    Kanamori, N
    Takayama, T
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2002, 128 (09) : 493 - 496
  • [26] Sequential chemotherapy with cisplatin, leucovorin, and 5-fluorouracil followed by docetaxel in previously untreated patients with metastatic gastric cancer: a phase II study
    Catalano, Vincenzo
    Vincenzi, Bruno
    Giordani, Paolo
    Graziano, Francesco
    Santini, Daniele
    Baldelli, Anna Maria
    Alessandroni, Paolo
    Schiavon, Gaia
    Rossi, David
    Casadei, Virginia
    D'Emidio, Silvia
    Fedeli, Stefano Luzi
    Tonini, Giuseppe
    Fiorentini, Giammaria
    GASTRIC CANCER, 2012, 15 (04) : 419 - 426
  • [27] Docetaxel, cisplatin, UFT and leucovorin combination chemotherapy in advanced gastric cancer.
    Oh, SC
    Sung, S
    Park, G
    Choi, I
    Seo, JH
    Choi, C
    Kim, B
    Shin, S
    Kim, Y
    Kim, JS
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 371S - 371S
  • [28] Oxaliplatin, 5-fluorouracil and Leucovorin (FOLFOX-4) Combination Chemotherapy as a Salvage Treatment in Advanced Gastric Cancer
    Kim, Young Saing
    Hong, Junshik
    Sym, Sun Jin
    Park, Se Hoon
    Park, Jinny
    Cho, Eun Kyung
    Lee, Jae Hoon
    Shin, Dong Bok
    CANCER RESEARCH AND TREATMENT, 2010, 42 (01): : 24 - 29
  • [29] Docetaxel, 5-fluorouracil, and leucovorin as treatment for advanced gastric cancer: Results of a phase II study
    Constenla M.
    Garcia-Arroyo R.
    Lorenzo I.
    Carrete N.
    Campos B.
    Palacios P.
    Gastric Cancer, 2002, 5 (3) : 142 - 147
  • [30] Comparison of neoadjuvant chemotherapy and postoperative adjuvant chemotherapy in the treatment of Borrmann type IV gastric cancer.
    Huang, Xingmao
    Yu Pengfei
    Fang, Jingquan
    Cao, Yang
    Ye, Zeyao
    Chai, Tengjiao
    Du, Yian
    Cheng, Xiangdong
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16) : E16064 - E16064